Tag Archives: VX-661

August, 2016

  • 17 August

    Vertex to Stop of Experimental Cystic Fibrosis Phase 3 Combo Trial

    BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies that together are expected to enroll more than 1,000 people with cystic fibrosis (CF). Based on a planned interim futility …

March, 2015